Objectives: To differentiate the impact of the b-blocking and the anti-oxidant activity of carvedilol in maintaining myocardium viability. Methods: Isolated rabbit hearts, subjected to aerobic perfusion, or low-flow ischaemia followed by reperfusion, were treated with two doses of carvedilol, one dose (2.0 mM) with marked negative inotropic effect due to b-blockage and the other (0.1 mM) with no b-blockage nor negative inotropism. Carvedilol was compared with two doses of propranolol, 1.0 -without -and 5.0 mM -with negative inotropic effect. Anti-oxidant activity was measured as the capacity to counteract the occurrence of oxidative stress and myocardium viability as recovery of left ventricular function on reperfusion, membrane damage and energetic status. Results: Carvedilol counteracted the ischemia and reperfusion induced oxidative stress: myocardial content of reduced glutathione, protein and non-protein sulfhydryl groups after ischaemia and particularly after reperfusion, was higher in hearts treated with carvedilol, while the myocardial content of oxidised glutathione was significantly reduced (0.3060.03 and 0.2160.02 vs. 0.3960.03 nmol / mg prot, both P,0.01, in 0.1 and 2.0 mM). At the same time, carvedilol improved myocardium viability independently from its b-blocking effect. On the contrary, propranolol maintained viability only at the higher dose, although to a lesser extent than carvedilol. This suggests that the effects of propranolol are dependent on energy saving due to negative inotropism. The extra-protection observed with carvedilol at both doses is likely due to its anti-oxidant effect. Conclusions: Our data show that the anti-oxidant activity of carvedilol is relevant for the maintenance of myocardium viability.
Introduction
Carvedilol is an effective b-blocking cardioprotective agent with a-blocking and anti-oxidant properties [3] [4] [5] . Besides their use in hypertension and myocardial infarc-
The anti-oxidant action may be relevant to preserve tion (MI), b-blockers have been considered in the therapy myocardium viability, particularly during ischaemia and of post-ischaemic left ventricular (LV) dysfunction and reperfusion, conditions linked to the occurrence of oxidaheart failure (HF) [1, 2] . Their efficacy in these conditions tive stress [6] [7] [8] [9] [10] [11] [12] [13] . cannot be explained only by the b-blocking activity: other Thus, the aim of our study was to differentiate the 'ancillary' properties, such as the anti-oxidant activity, impact of the b-blocking and the anti-oxidant activities in may be important [3] .
the carvedilol-induced maintenance of viability of the ischaemic myocardium. Previous studies were performed using carvedilol's doses which, by exerting negative inotropic effects, reduced heart work [7, 8, 11, 12] . Thus, 2.2. Experimental conditions these studies could not discriminate whether the preserved anti-oxidant state by carvedilol was secondary to its After 45 min of aerobic equilibration (time zero as cardio-protective activity -due to energy saving -or baseline condition) with CF of 25 ml / min, the hearts were played an active role by itself.
subjected to: (a) 90 min of aerobic perfusion, or (b) 60 min We used isolated crystalloid perfused paced rabbit of global, severe low-flow ischaemia (CF50.5 ml / min), or hearts, as this model clearly show the b-blocking activity (c) 60 min of ischaemia followed by 3 min of reperfusion in terms of negative inotropic effect. Moreover, by using at CF of 25 ml / min, or (d) 60 min of ischaemia followed different doses of the tested drug, with or without negative by 30 min of reperfusion. LV function was monitored and inotropism, we tried to determine whether the anti-oxidant 2.5-ml aliquots of coronary effluent were timely collected. properties of carvedilol contributed to its cardio-protective At the end of each perfusion, hearts were frozen with effect.
pre-cooled Wollemberger tongs and stored in liquid nitroIn accordance with the experimental design, we degen, until the relevant determinations were carried out. termined:
2.3. Experimental groups 1. Myocardium viability, measured in terms of: (a) LV function assessed as systolic, diastolic and coronary The hearts were randomly divided into: perfusion pressures, (b) membrane damage assessed as creatine phosphokinase (CPK) release, and (c) cellular
• Control hearts (n530), receiving perfusion buffer energetic status assessed as high energy phosphate
• Carvedilol-treated hearts (n549). On the basis of content and cellular redox status preliminary dose-response curve studies, carvedilol 2. Oxidative stress, inferred as the 'anti-oxidant / oxidant was used at two concentrations: 0.1 mM, which has no status' which was measured by reduced and oxidised negative inotropic effect, and 2.0 mM, with marked glutathione (GSH and GSSG, respectively) metabolism negative inotropic effects and sulfhydryl group (SH) contents.
• Propranolol-treated hearts (n547), receiving two dosages of propranolol, i.e. 1.0 and 5.0 mM, the former lacking a significant negative inotropic effect and the In addition, we compared the effects of carvedilol with latter showing such an effect those of propranolol, used at two dosages: these dosages did not possess any anti-oxidant effect [14, 15] , and one of them exerted a negative inotropic effect.
Each treatment was carried out 30 min before ischaemia and throughout the experiment.
CPK and glutathione release 2. Methods
Coronary effluent was collected in chilled glass vials The study was performed in accordance with European and assayed, on the same day, for CPK activity. An aliquot Union guidelines (86 / 609 / CEE) for the use and care of of 2.0 ml was added to 0.2 ml of 0.02 M EDTA for laboratory animals.
immediate GSH and GSSG determination. CPK was assayed spectrophotometrically by the Oliver method [17] while GSH and GSSG by the method of 2.1. Perfusion of the hearts Tietze [18] as previously described [16] .
A total of 126 male New Zealand white rabbits (2.0-2.3 kg), maintained on a standard diet, were used. They were 2.5. Assay of high-energy phosphates, purine and stunned by a blow to the neck. The hearts were quickly pyridine nucleotides removed and placed in ice-cold perfusion buffer (48C) and perfused as previously described [16] . The perfusion After each perfusion, the hearts were freeze-clamped solution was warmed to 378C, bubbled with 95% O and with aluminium tongs which had been pre-cooled in liquid 2 5% CO , and delivered to the heart with a Gilson Minipuls nitrogen and stored in liquid nitrogen until the measure-2 2 rotary pump providing a coronary flow (CF) of 25 ments were carried out. High-energy phosphates, purine ml / min. Hearts were jacketed (40-448C) to provide a and pyridine nucleotides were extracted from frozen constant myocardial temperature of 378C independently tissues, both ground (mixed with 0.4 N HClO in liquid 4 from CF. The hearts were paced at a rate of 180 bpm [16] . nitrogen bath) and homogenised using an Ultra-Turrax, as LV function and coronary perfusion pressure were monipreviously described [19] . Separation and quantification of tored as described [16] .
the specifically extracted metabolites were performed by HPLC with the use of reversed-phase 3 mm C column, as P values ,0.05 were considered statistically significant. 18 previously described [19] . The control hearts slightly decreased their CPP (from 2 3 extract was analysed for total glutathione by the method of 41.767.2 to 33.165.0 mmHg) and were able to maintain Tietze [18] . GSSG was measured as described above, after developed pressure during aerobic perfusion (92.769.9% the preliminary reaction of GSH with 20 mM N-ethylof the starting value). Under the same conditions, carmaleimide followed by complete removal of unreacted vedilol at the higher dosage (2.0 mM), but not at 0.1 mM, sulfhydryl reagent with diethylether.
exerted negative inotropic effects [to 50.863.6% (P,0.01) Protein (P-SH) and non protein (NP-SH) -SH were of baseline developed pressures] (data not shown). determined as described by Sedlack and Lindsay [20] .
Propranolol at the dose of 5.0 mM exerted a marked negative inotropic action, reaching a developed pressure of 57.764.1% vs. baseline (P,0.01), while at 1.0 mM it did 2.7. Protein determination not have any effect (data not shown).
Neither carvedilol nor propranolol affected the CPP at This was carried out according to Bradford [21] , using any dosage. Diastolic pressure remained close to 0 mmHg bovine serum albumin as standard.
for the entire period of perfusion in each group. (Fig. 2B ). In comparison with Spearman's correlation coefficients among the variables ischaemic control hearts, carvedilol at 2.0 mM: (a) measuring the oxidative stress (expressed as GSH / GSSG abolished any rise in diastolic pressure both during isafter 30 min of reperfusion), diastolic pressure and total chaemia and reperfusion, (b) increased recovery of de-CPK release measured during reperfusion (area under the veloped pressure (97.465.0 vs. 34.1614.6%, P,0.01), curves), were calculated.
( Fig. 2B ), (c) reduced the reperfusion-induced rise of CPP Since our data-sets consisted also of repeated measures, (66.869.7 vs. 72.965.0 mmHg) (data not shown). Also, we performed an analysis of variance for repeated mea-1.0 mM propranolol had no effect on the mechanical sures. With this model, we have analysed the following function of the isolated heart either during ischaemia or parameters: systolic pressure, diastolic pressure, CPK, reperfusion. On the contrary, the higher dosage (5.0 mM) GSH and GSSG releases in relation to time.
preserved mechanical function, although the degree of The statistical packages SAS (SAS Institute Inc., Cary, cardiac protection was smaller than that exerted by car-NC, USA) was used to perform the statistical analysis.
vedilol at the dose of 2.0 mM (Fig. 2C) . end of perfusion). Treatment with either carvedilol or hearts (0.8060.04 vs. 0.6460.01, P,0.05). Reperfusion propranolol had no effect, independently from the doses further improved these parameters, suggesting a recovery (data not shown).
of the aerobic metabolism. Propranolol, at the dose of 1.0 mM, failed to improve 3.1.2.2. Ischaemia and reperfusion studies In control cardiac metabolism either after ischaemia or reperfusion. hearts a marked membrane damage was observed. During
The increase of the dose resulted in an improvement ischaemia, in view of the severe reduction of the CF, CPK similar to that observed with the higher dose of carvedilol. release was not different from aerobic conditions. However, during reperfusion, a progressive and massive CPK 3.2. Oxidative stress release was detected (from 37.865.9 to 1816.76200.1 mU / min / g wet weight (g ww), at 1 and 30 min reperfu-3.2.1. Aerobic perfusion studies sion, respectively) (Fig. 3A) .
In both control and treated hearts, with either carvedilol A significant reduction of CPK release during reperfuor propranolol, no differences in GSH, GSSG, P-and sion was observed with 0.1 mM carvedilol (1250.66174.6
NP-SH (similar to the results for the other parameters) vs. 1816.76200.1 mU / min / g ww, P,0.05). Carvedilol at were observed. The release of GSH and GSSG was 2.0 mM almost abolished CPK leakage (309.6619.9 vs. negligible and unaffected by the treatment (data not 1816.76200.1 mU / min / g ww, P,0.001) (Fig. 3A) .
shown). On the contrary, the lower dose of propranolol, which lacked b-blocking effects in terms of mechanical function, 3.2.2. Ischaemia and reperfusion studies had no effect on CPK release during reperfusion A significant oxidative stress mostly occurring on (1848.36404.3 vs. 1816.76200.1 mU / min / g ww) (Fig. reperfusion was observed in control hearts. As expected, 3A). At the higher dosage, propranolol almost abolished the rate of GSH and GSSG release was negligible during the reperfusion-induced CPK release (P,0.01).
ischaemia but increased remarkably after reperfusion (Fig.  3B,C) . At the end of ischaemia, GSH / GSSG ratio de-3. nmol / mg prot observed under aerobic conditions), despite alteration of the cellular energetic status was observed in the continuous release, which suggests the occurrence of control hearts. Ischaemia caused a severe depletion of CP oxidative stress (Fig. 3C) . Consequently, GSH / GSSG ratio and a less severe reduction of ATP. AMP increased further decreased (Table 2) . P-and NP-SH decreased from proportionally; energy charge decreased from 0.9160.03 231.6615.3 to 122.568.2 and from 21.463.6 to 10.361.0 to 0.6460.01 (P,0.01) and the ratio of oxidized and nmol / mg prot at early reperfusion (P,0.01) and to reduced nicotinamide adenine dinucleotide (NAD/ NADH) 138.465.2 and to 12.360.7 nmol / mg prot, at late reperfudropped from 8.760.5 to 1.060.1 (P,0.01). Reperfusion sion (P,0.01) ( Table 2) . caused an additional drop in ATP without any recovery of Carvedilol delayed and counteracted the occurrence of the other parameters.
oxidative stress during ischaemia and reperfusion. GSH, PTreatment with carvedilol at 0.1 mM had no effect on and NP-SH myocardial contents were higher in treated the metabolic changes induced by ischaemia. However, it hearts and myocardial GSSG accumulation and release increased the recovery of energetic metabolism during were significantly (P,0.01) reduced in a similar pattern in reperfusion. In particular, at the end of reperfusion, ATP all carvedilol 0.1 and 2.0 mM treated hearts vs. ischaemic content was 10 Table 2 ). ATP and CP was significantly reduced; NAD/ NADH ratio The 5.0-mM propranolol significantly preserved myocarwas also better maintained. As a consequence, energy dial thiolic group contents and attenuated GSSG accumulacharge at the end of ischaemia was higher than in control tion and release, as well. However, the degree of protection against oxidative stress was less than that obtained by 2.0 3.3. Correlations mM carvedilol. At 1.0 mM, propranolol showed no improvement, while 0.1 mM carvedilol -which did not
We observed a link between carvedilol's anti-oxidant affect baseline contractile function -significantly reduced and cardio-protective effects. In particular, we found a oxidative stress (Fig. 3B,C and ratio (at the end of reperfusion) and total CPK release propranolol since they are independent from its bduring reperfusion considering both / all groups (n534; blocking and negative inotropic effect r520.674, P,0.001) and only 0.1 mM carvedilol group 3. The anti-oxidant activity of carvedilol may be important (n57; r520.782, P50.038). We obtained similar findings in explaining the extra-protection occurring in respect comparing GSH / GSSG ratio with diastolic pressure into propranolol crease (r520.712, P,0.001 in all groups and r520.730, P50.043 in 0.1 mM carvedilol).
4.1. Improvement of ischaemic myocardium viability It is interesting to underline that, in 0.1 mM carvedilol with carvedilol at negative inotropic doses group, no significant correlation was found between GSH / GSSG ratio and ATP (n57; r50.570, P50.181) and CP In vivo, carvedilol exerts an a -adrenergic blocking 1 (n57; r50.527, P50.224) myocardial contents. activity, and, through this mechanism, it may be cardioprotective by unloading the heart. It also reduces heart rate and could, through this mechanism, reduce the myocardial oxygen consumption. However, none of these effects may 4. Discussion be considered as having occurred in our experimental model, which was independent from pre-and after-load, Our data suggest that:
and in which the hearts were constantly paced. In vitro, b-blockers are usually cardioprotective through 1. Carvedilol improves myocardium viability in ischaemic their negative inotropic effect [22] . In fact, there is an and perfused hearts and its effect is better than propraninverse relationship between the degree of contraction olol before ischaemia and ATP content at the end of ischaemia 2. Some of the effects of carvedilol differ from those of [23] . This was indeed the case for both carvedilol and aerobia and ischaemia, P , the significance of difference between values after aerobia and early reperfusion; P , the significance of difference between 2 3 values after aerobia and late reperfusion; P , the significance of difference between values after early and late reperfusion; GSH, reduced glutathione; 4 GSSG, oxidised glutathione; P-SH, protein sulfhydryl groups; NP-SH, non-protein sulfhydryl groups. * Indicates P,0.05 significant difference vs. control. ** P,0.01 significant difference vs. control.
propranolol when used at doses which exerted negative ised cardiac protection due to the b-blocking-mediated inotropic effects as a result of the b-blockage. In both energy saving. cases ATP was better maintained at the end of ischaemia.
However, the effects of carvedilol on diastolic function, In this condition, readmission of oxygen with reperfusion CPK release and recovery of function on reperfusion, were results in a prompt recovery of intermediate metabolism.
superior to those exerted by propranolol which was This is suggested by the observed re-oxidation of NADH deliberately used at a dose causing identical negative which has been accumulated during ischaemia (Table 1) . It inotropic and energy saving effects. Interestingly, the is known that both cytosolic and mitochondrial NAD/ effects on oxidative stress were also more evident with NADH pools are affected by ischaemia and reperfusion carvedilol than with propranolol, suggesting that the direct conditions. The method for determining NAD/ NADH anti-oxidant capacity of carvedilol could have played an couple that we used in our study does not distinguish the additional role. This hypothesis is supported by the data possible compartmentalisation of pyridinic nucleotides (i.e. obtained using carvedilol at 0.1 mM. mitochondrial vs. cytosolic). However, NAD/ NADH measurement in the whole homogenate, mainly represented by 4.2. Improvement of ischaemic myocardium viability in the mitochondrial fraction, is a good approximation of the absence of negative inotropic effects actual status of the Krebs cycle [24, 25] . In turn, the decrease of cellular accumulation of NADH, putatively When used at 0.1 mM, carvedilol had no effect on due to re-established electron-flow through respiratory inotropism or on energy metabolism and actually mainchain, leads to increased tissue contents of high-energy tained myocardium viability and recovery on reperfusion. phosphates.
This was not the case for propranolol. Thus, the issue is: A reduced energy breakdown during ischaemia is ex-'could this effect of carvedilol, as well as its extra-protecpected to maintain cellular viability, thus avoiding memtion in respect to propranolol, be a consequence of its brane damage, alteration of ionic homeostasis and the anti-oxidant activity'? Actually, our data support this occurrence of oxidative stress. Therefore, the positive hypothesis. effects on glutathione and -SH group metabolism which
We measured oxidative stress in terms of glutathione we found after treatment with high doses of carvedilol and metabolism. Glutathione system plays a crucial role in the propranolol are most likely the consequence of a generalmyocyte: GSH works as a reducing equivalent donor, auto-oxidising to GSSG which is reconverted into the of its anti-oxidant activity. Obviously, the above mechareduced form at the expense of NADPH via glutathione nism cannot be accepted tout cour, since other factors can reductase. Oxidant conditions, such as post-ischaemic intervene in this effect. However, in our in vitro model, reperfusion, both in humans and in experimental models, alternative mechanisms are difficult to identify since all the induce accumulation of GSSG and reduction of cellular variables were kept under control. The actual relevance of thiol groups in the myocardium [26] [27] [28] [29] . Thus, myocardial carvedilol's anti-oxidant activity in cardioprotection should GSSG content and release are reliable and specific indices be investigated in more complex in vivo models. of oxidative stress suitable to test the anti-oxidant capacity of a drug [16, [30] [31] [32] .
In our experiments, 0.1 mM carvedilol showed its
